142 related articles for article (PubMed ID: 31057013)
1. Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy.
Mariotto S; Tecchio C; Sorio M; Bertolasi L; Turatti M; Tozzi MC; Benedetti F; Cavaletti G; Monaco S; Ferrari S
Leuk Lymphoma; 2019 Nov; 60(11):2806-2809. PubMed ID: 31057013
[No Abstract] [Full Text] [Related]
2. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
Izutsu K; Ogura M; Tobinai K; Hatake K; Sakamoto S; Nishimura M; Hoshino M
Int J Hematol; 2021 Mar; 113(3):404-412. PubMed ID: 33392974
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies.
Fargeot G; Dupel-Pottier C; Stephant M; Lazarovici J; Thomas L; Mouthon-Reignier C; Riad B; Carde P; Berzero G; Tafani C; Nicolas W; Viala K; Maisonobe T; Lenglet T; Wang A; Magy L; Bihan K; Gaspar N; Adams D; Echaniz-Laguna A; Cauquil C; Psimaras D
J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):786-788. PubMed ID: 32327451
[No Abstract] [Full Text] [Related]
5. The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
McMillan A; O'Neill AT; Townsend W; Lambert J; Virchis A; Shah R; Menezes L; Humphries P; Von Both K; Grandage V; Carpenter B; Hough R; Ardeshna KM; Daw S
Br J Haematol; 2021 Feb; 192(3):e84-e87. PubMed ID: 33426648
[No Abstract] [Full Text] [Related]
6. FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?
Milunović V; Mišura Jakobac K; Kursar M; Mandac Rogulj I; Ostojić Kolonić S
Eur J Haematol; 2019 Sep; 103(3):145-151. PubMed ID: 31166030
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus Pneumonia Causing Acute Respiratory Distress Syndrome After Brentuximab Vedotin Therapy.
Tambe A; Gentile T; Ramadas P; Tambe V; Badrinath M
Am J Ther; 2019; 26(6):e794-e795. PubMed ID: 31436571
[No Abstract] [Full Text] [Related]
8. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan.
Tien FM; Tsai CH; Liu JH; Lin CT
J Formos Med Assoc; 2019 Oct; 118(10):1466-1470. PubMed ID: 31337522
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group.
Damaschin C; Goergen H; Kreissl S; Plütschow A; Breywisch F; Mathas S; Meissner J; Sökler M; Topp MS; Vucinic V; Zimmermann A; von Tresckow B; Fuchs M; Engert A; Borchmann P; Eichenauer DA
Leukemia; 2022 Feb; 36(2):580-582. PubMed ID: 34408266
[No Abstract] [Full Text] [Related]
10. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T
J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.
Garciaz S; Loschi M; De Masson A; Biard L; Mercier M; Tomowiak C; Delage J; Labussiere-Wallet H; Sibon D; Cassuto O; Borel C; Cornillon J; Nimubona S; Charbonnier A; Brice P; Socié G; Bouabdallah R; de Latour RP; de Fontbrune FS
Leuk Lymphoma; 2019 Nov; 60(11):2802-2805. PubMed ID: 31014144
[No Abstract] [Full Text] [Related]
12. Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma.
Kallam A; Vose JM
Oncology (Williston Park); 2019 May; 33(5):192-8. PubMed ID: 31095720
[TBL] [Abstract][Full Text] [Related]
13. Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis.
Gao S; Zhang M; Wu K; Zhu J; He Z; Li J; Chen C; Qiu K; Yu X; Wu J
Expert Opin Drug Saf; 2020 May; 19(5):617-623. PubMed ID: 31955620
[No Abstract] [Full Text] [Related]
14. Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin.
Pastorelli F; Derenzini E; Plasmati R; Pellegrini C; Broccoli A; Casadei B; Argnani L; Salvi F; Pileri S; Zinzani PL
Leuk Lymphoma; 2013 Oct; 54(10):2318-21. PubMed ID: 23391144
[No Abstract] [Full Text] [Related]
15. Adverse reactions related to brentuximab vedotin use: A real-life retrospective study.
Clarivet B; Vincent L; Vergely L; Bres V; Foglia K; Cartron G; Hillaire-Buys D; Faillie JL
Therapie; 2019 Jun; 74(3):343-346. PubMed ID: 30177280
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.
Suri A; Mould DR; Song G; Collins GP; Endres CJ; Gomez-Navarro J; Venkatakrishnan K
Clin Pharmacol Ther; 2019 Dec; 106(6):1268-1279. PubMed ID: 31152605
[TBL] [Abstract][Full Text] [Related]
17. Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy.
Matthys A; Bardel B; Le Bras F; Créange A; Nordine T; Gounot R; Ingen-Housz-Oro S; Carvalho M; Lefaucheur JP; Haioun C; Planté-Bordeneuve V; Gendre T
Eur J Neurol; 2024 Jul; 31(7):e16285. PubMed ID: 38511878
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin as consolidation after hematopoietic cell transplant for relapsed Hodgkin lymphoma in pediatric patients.
Flerlage JE; von Buttlar X; Krasin M; Triplett B; Kaste SC; Metzger ML
Pediatr Blood Cancer; 2019 Dec; 66(12):e27962. PubMed ID: 31429511
[No Abstract] [Full Text] [Related]
19. Acute liver injury leading to death in the setting of brentuximab vedotin monotherapy.
Neeman J; Friedman A; McKendrick J
Leuk Lymphoma; 2019 Sep; 60(9):2283-2286. PubMed ID: 30822188
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin monotherapy is an effective treatment in a frail pediatric patient with Down syndrome and classical Hodgkin lymphoma.
Vonasek J; Edslev PW; d'Amore F; Hasle H
Pediatr Blood Cancer; 2020 Feb; 67(2):e28082. PubMed ID: 31724794
[No Abstract] [Full Text] [Related]
[Next] [New Search]
